In preclinical tumor and viral models, combining individual agents, such as IL-2v plus anti-PD1, was far less efficacious for disease control than single agents, such as the anti-PD1‒IL2v agent, highlighting the advantage of cis-targeting IL-2 on the right cell type in subsequent cytokine therapies. Here, IL2 is linked to neoplasm.